<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36776887</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The COVID-19, tuberculosis and HIV/AIDS: M&#xe9;nage &#xe0; Trois.</ArticleTitle><Pagination><StartPage>1104828</StartPage><MedlinePgn>1104828</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1104828</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1104828</ELocationID><Abstract><AbstractText>In December 2019, a novel pneumonic condition, Coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in China and spread globally. The presentation of COVID-19 is more severe in persons with underlying medical conditions such as Tuberculosis (TB), Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and other pneumonic conditions. All three diseases are of global concern and can significantly affect the lungs with characteristic cytokine storm, immunosuppression, and respiratory failure. Co-infections of SARS-CoV-2 with HIV and <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) have been reported, which may influence their pathogenesis and disease progression. Pulmonary TB and HIV/AIDS patients could be more susceptible to SARS-CoV-2 infection leading to lethal synergy and disease severity. Therefore, the biological and epidemiological interactions of COVID-19, HIV/AIDS, and TB need to be understood holistically. While data is needed to predict the impact of the COVID-19 pandemic on these existing diseases, it is necessary to review the implications of the evolving COVID-19 management on HIV/AIDS and TB control, including therapy and funding. Also, the impact of long COVID on patients, who may have this co-infection. Thus, this review highlights the implications of COVID-19, HIV/AIDS, and TB co-infection compares disease mechanisms, addresses growing concerns, and suggests a direction for improved diagnosis and general management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Udoakang, Djomkam Zune, Tapela, Nganyewo, Olisaka, Anyigba, Tawiah-Eshun, Owusu, Paemka, Awandare and Quashie.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Udoakang</LastName><ForeName>Aniefiok John</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biosciences and Biotechnology, University of Medical Sciences, Ondo, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djomkam Zune</LastName><ForeName>Alexandra Lindsey</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapela</LastName><ForeName>Kesego</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nganyewo</LastName><ForeName>Nora Nghochuzie</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olisaka</LastName><ForeName>Frances Ngozi</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Environmental and Public Health Microbiology, Department of Biological Science, Benson Idahosa University, Benin City, Edo State, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anyigba</LastName><ForeName>Claudia Adzo</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tawiah-Eshun</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Korle-bu Teaching Hospital, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owusu</LastName><ForeName>Irene Amoakoh</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paemka</LastName><ForeName>Lily</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awandare</LastName><ForeName>Gordon A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quashie</LastName><ForeName>Peter Kojo</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="Y">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HIV/AIDS</Keyword><Keyword MajorTopicYN="N">co-infection</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">susceptibility</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>13</Day><Hour>3</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36776887</ArticleId><ArticleId IdType="pmc">PMC9911459</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1104828</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization . WHO director-general&#x2019;s opening remarks at the media briefing on COVID-19 - 11 march 2020 (2020). Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19&#x2014;11-march-2020.</Citation></Reference><Reference><Citation>Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918-1920 &#x201c;Spanish&#x201d; influenza pandemic. Bull Hist Med (2002) 76(1):105&#x2013;15. doi: 10.1353/bhm.2002.0022</Citation><ArticleIdList><ArticleId IdType="doi">10.1353/bhm.2002.0022</ArticleId><ArticleId IdType="pubmed">11875246</ArticleId></ArticleIdList></Reference><Reference><Citation>
Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. In: Bulletin of the history of medicine (United States: Johns Hopkins University Press; ) (1991) 65(1):4&#x2013;21. Available at: https://pubmed.ncbi.nlm.nih.gov/2021692/.</Citation><ArticleIdList><ArticleId IdType="pubmed">2021692</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . WHO coronavirus (COVID-19) dashboard | WHO coronavirus (COVID-19) dashboard with vaccination data (2022). Available at: https://covid19.who.int/.</Citation></Reference><Reference><Citation>
World Health Organization . Naming the coronavirus disease (COVID-19) and the virus that causes it (2020). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395(10223):497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: A biomarker for COVID-19. Int Forum Allergy Rhinol (2020) 10(8):944&#x2013;50. doi:&#xa0;10.1002/alr.22587</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22587</ArticleId><ArticleId IdType="pmc">PMC7262123</ArticleId><ArticleId IdType="pubmed">32301284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China. JAMA Neurol (2020) 77(6):683&#x2013;90. doi: 10.1001/jamaneurol.2020.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Chu M, Zhong F, Tan X, Tang G, Mai J, et al. . Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell Death Discovery (2020) 6(1):76. doi: 10.1038/s41420-020-00307-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-020-00307-w</ArticleId><ArticleId IdType="pmc">PMC7417862</ArticleId><ArticleId IdType="pubmed">32818075</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Z, Yi F, Wu K, Lai K, Sun X, Zhong N, et al. . Clinical characteristics of coronavirus disease 2019 (COVID-19): An updated systematic review. medRxiv (2020) doi:&#xa0;10.1101/2020.03.07.20032573</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.07.20032573</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M&#xfc;ller MA, et al. . Virological assessment of hospitalized patients with COVID-2019. Nature (2020) 581(7809):465&#x2013;9. doi: 10.1038/s41586-020-2196-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>
Center for Disease Control and Prevention . Long COVID or post-COVID conditions. CDC (2022) United States: U.S. Department of Health &amp; Human Services. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. . HIV Infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV (2021) 8(1):e24&#x2013;32. doi: 10.1016/S2352-3018(20)30305-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(20)30305-2</ArticleId><ArticleId IdType="pmc">PMC7773630</ArticleId><ArticleId IdType="pubmed">33316211</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadolini M, Codecasa LR, Garc&#xed;a-Garc&#xed;a JM, Blanc FX, Borisov S, Alffenaar JW, et al. . Froissart sequelae and c-19 co-infection: First cohort of 49 cases. active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J (2020) 56(1):2001398. doi:&#xa0;10.1183/13993003.01398-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01398-2020</ArticleId><ArticleId IdType="pmc">PMC7251245</ArticleId><ArticleId IdType="pubmed">32457198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Wang CY, Hsueh PR. Co-Infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infection (2020) 53(4):505&#x2013;512. doi: 10.1016/j.jmii.2020.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.05.013</ArticleId><ArticleId IdType="pmc">PMC7245213</ArticleId><ArticleId IdType="pubmed">32482366</ArticleId></ArticleIdList></Reference><Reference><Citation>Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. . Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA - J Am Med Assoc (2020) 323(16):1612&#x2013;14. doi:&#xa0;10.1001/jama.2020.4326</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4326</ArticleId><ArticleId IdType="pmc">PMC7082763</ArticleId><ArticleId IdType="pubmed">32191259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in wuhan, China. J Med Virol (2020) 92(9):1549&#x2013;55. doi:&#xa0;10.1002/jmv.25781</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25781</ArticleId><ArticleId IdType="pmc">PMC7228290</ArticleId><ArticleId IdType="pubmed">32196707</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak MD, Sordillo EM, Gitman MR, Paniz Mondolfi AE. Co-Infection in SARS-CoV-2 infected patients: Where are influenza virus and Rhinovirus/Enterovirus? J Med Virol (2020) 92(10):1699&#x2013;700. doi: 10.1002/jmv.25953</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25953</ArticleId><ArticleId IdType="pmc">PMC7267652</ArticleId><ArticleId IdType="pubmed">32352574</ArticleId></ArticleIdList></Reference><Reference><Citation>Pongpirul WA, Mott JA, Woodring JV, Uyeki TM, MacArthur JR, Vachiraphan A, et al. . Clinical characteristics of patients hospitalized with coronavirus disease, Thailand. Emerg Infect Dis (2020) 26(7):1580&#x2013;5. doi: 10.3201/eid2607.200598</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.200598</ArticleId><ArticleId IdType="pmc">PMC7323520</ArticleId><ArticleId IdType="pubmed">32267826</ArticleId></ArticleIdList></Reference><Reference><Citation>Touzard-Romo F, Tap&#xe9; C, Lonks JR. Co-Infection with SARS-CoV-2 and human metapneumovirus. R I Med J (2013) 103(2):75&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32192233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. . Co-Infection with SARS-CoV-2 and influenza a virus in patient with pneumonia, China. Emerg Infect Dis (2020) 26(6):1324&#x2013;6. doi: 10.3201/eid2606.200299</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2606.200299</ArticleId><ArticleId IdType="pmc">PMC7258479</ArticleId><ArticleId IdType="pubmed">32160148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z, Cheng S, Le J, Huang J, Feng L, Zhang B, et al. . Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in wuhan, China: a retrospective cohort study. Microbes Infect (2020) 22(4-5):195&#x2013;9. doi: 10.1016/j.micinf.2020.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7233257</ArticleId><ArticleId IdType="pubmed">32425649</ArticleId></ArticleIdList></Reference><Reference><Citation>
Long COVID more common in people with HIV | aidsmap (2022). Available at: https://www.aidsmap.com/news/mar-2022/long-covid-more-common-people-hiv.</Citation></Reference><Reference><Citation>Samannodi M, Alwafi H, Naser AY, Qurashi AAAL, Qedair JT, Salawati E, et al. . Determinants of post-COVID-19 conditions among SARS-CoV-2-Infected patients in Saudi Arabia: A web-based cross-sectional study. Diseases (2022) 10(3):55. doi: 10.3390/diseases10030055</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases10030055</ArticleId><ArticleId IdType="pmc">PMC9497712</ArticleId><ArticleId IdType="pubmed">36135212</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK - office for national statistics (2021). Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021.</Citation></Reference><Reference><Citation>
Natinal Institute of Health . HIV | COVID-19 treatment guidelines (2022). Available at: https://www.covid19treatmentguidelines.nih.gov/special-populations/hiv/.</Citation></Reference><Reference><Citation>Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 among people living with HIV: A systematic review. United States of America: Springer; (2020). doi:&#xa0;10.1007/s10461-020-02983-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-020-02983-2</ArticleId><ArticleId IdType="pmc">PMC7391049</ArticleId><ArticleId IdType="pubmed">32734438</ArticleId></ArticleIdList></Reference><Reference><Citation>
United Nations Programme on HIV and AIDS . Global HIV &amp; AIDS statistics &#x2014; fact sheet. Geneva, Switzerland: UNAIDS;  (2022). Available at: https://www.unaids.org/en/resources/fact-sheet.</Citation></Reference><Reference><Citation>
United Nations Programme on HIV and AIDS . Fact sheet - world tuberculosis day 2022 (2022). Available at: https://www.unaids.org/sites/default/files/media_asset/20220324_TB_FactSheet_en.pdf.</Citation></Reference><Reference><Citation>Riou J, Althaus CL. Pattern of early human-to-human transmission of wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. vol. 25, eurosurveillance. Stockholm, Sweden: European Centre for Disease Prevention and Control (ECDC; (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7001239</ArticleId><ArticleId IdType="pubmed">32019669</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, Lederman MM, et al. . HIV Long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. Aids (2002) 16(8):1113&#x2013;8. doi: 10.1097/00002030-200205240-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-200205240-00004</ArticleId><ArticleId IdType="pubmed">12004269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski A, Jansson M, Sk&#xf6;ld M, Rottenberg ME, K&#xe4;llenius G. Tuberculosis and HIV Co-infection. PloS Pathog (2012) 8(2):e1002464. doi:&#xa0;10.1371/journal.ppat.1002464</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002464</ArticleId><ArticleId IdType="pmc">PMC3280977</ArticleId><ArticleId IdType="pubmed">22363214</ArticleId></ArticleIdList></Reference><Reference><Citation>Geneva: World Health Organization . Global tuberculosis report (Geneva, Switzerland: World Health Organization; ), Vol. 2021. (2021).</Citation></Reference><Reference><Citation>
World Health Organization . Tuberculosis (TB). Brazzaville, Republic of Congo: WHO | Regional Office for Africa;  (2022). Available at: https://www.afro.who.int/health-topics/tuberculosis-tb.</Citation></Reference><Reference><Citation>World Health Organization . Global tuberculosis report 2019. Geneva: World Health Organization; (2019).</Citation></Reference><Reference><Citation>Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and mycobacterium tuberculosis co-infection. Nat Rev Microbiol (2018) 16(2):80&#x2013;90. doi: 10.1038/nrmicro.2017.128</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.128</ArticleId><ArticleId IdType="pubmed">29109555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramkissoon S, Mwambi HG, Matthews AP. Modelling HIV and MTB Co-infection including combined treatment strategies. PloS One (2012) 7(11):e49492. doi: 10.1371/journal.pone.0049492</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049492</ArticleId><ArticleId IdType="pmc">PMC3509125</ArticleId><ArticleId IdType="pubmed">23209581</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Hsu ACY, Pang Z, Pan H, Zuo X, Wang G, et al. . Role of the innate cytokine storm induced by the influenza a virus. Viral Immunol (2019) 32(6):244&#x2013;51. doi: 10.1089/vim.2019.0032</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2019.0032</ArticleId><ArticleId IdType="pubmed">31188076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the &#x201c;Cytokine storm&#x201d; in COVID-19. J Infect (2020) 80(6):607&#x2013;13. doi:&#xa0;10.1016/j.jinf.2020.03.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.037</ArticleId><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun (2020) 109:102433. doi:&#xa0;10.1016/j.jaut.2020.102433</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102433</ArticleId><ArticleId IdType="pmc">PMC7127067</ArticleId><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. . Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses (2020) 12(4):372. doi: 10.3390/v12040372</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12040372</ArticleId><ArticleId IdType="pmc">PMC7232198</ArticleId><ArticleId IdType="pubmed">32230900</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol (2020) 20(5):269&#x2013;70. doi:&#xa0;10.1038/s41577-020-0308-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Wang X. COVID-19 : a new challenge for human beings. Cell Mol Immunol (2020) 17:555&#x2013;557, 19&#x2013;21. doi:&#xa0;10.1038/s41423-020-0407-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0407-x</ArticleId><ArticleId IdType="pmc">PMC7110263</ArticleId><ArticleId IdType="pubmed">32235915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T, Immunity M--. U. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity (2020) 52(5):731&#x2013;3. doi:&#xa0;10.1016/j.immuni.2020.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7175868</ArticleId><ArticleId IdType="pubmed">32325025</ArticleId></ArticleIdList></Reference><Reference><Citation>de Martino M, Lodi L, Galli L, Chiappini E. Immune response to mycobacterium tuberculosis: A narrative review. Front Pediatr (2019) 7:350. doi: 10.3389/fped.2019.00350</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00350</ArticleId><ArticleId IdType="pmc">PMC6718705</ArticleId><ArticleId IdType="pubmed">31508399</ArticleId></ArticleIdList></Reference><Reference><Citation>Etna MP, Giacomini E, Severa M, Coccia EM. Pro-and anti-inflammatory cytokines in tuberculosis: A two-edged sword in TB pathogenesis. Semin Immunol (2014) 26:543&#x2013;51. doi: 10.1016/j.smim.2014.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2014.09.011</ArticleId><ArticleId IdType="pubmed">25453229</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyanti LE, Wong ZH, Sachdev Manjit Singh B, Chang AKW, Jobli AT, Chua HH. Pulmonary tuberculosis and COVID-19 coinfection: Hickam&#x2019;s dictum revisited. Respir Med Case Rep (2022) 37:101653. doi:&#xa0;10.1016/j.rmcr.2022.101653</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2022.101653</ArticleId><ArticleId IdType="pmc">PMC9022463</ArticleId><ArticleId IdType="pubmed">35469213</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanickam A, Pavan Kumar N, Chandrasekaran P, Nancy A, Bhavani PK, Selvaraj N, et al. . Effect of SARS-CoV-2 seropositivity on antigen &#x2013; specific cytokine and chemokine responses in latent tuberculosis. Cytokine (2022) 150(155785). doi: 10.1016/j.cyto.2021.155785</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155785</ArticleId><ArticleId IdType="pmc">PMC8668379</ArticleId><ArticleId IdType="pubmed">34933240</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor L, Casellas A, Carrillo J, Alonso S, Parker E. IP-10 levels as an accurate screening tool to detect acute HIV infection in resource-limited settings. Sci Rep (2017) 7:1&#x2013;9. doi: 10.1038/s41598-017-08218-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08218-0</ArticleId><ArticleId IdType="pmc">PMC5556096</ArticleId><ArticleId IdType="pubmed">28808319</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor L, Parker E, Carrillo J, Urrea V, Fuente-Soro L, Respeito D, et al. . A cytokine pattern that differentiates preseroconversion from postseroconversion phases of primary HIV infection. J Acquir Immune Defic Syndr (2017) 74(4):459&#x2013;66. doi: 10.1097/QAI.0000000000001272</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000001272</ArticleId><ArticleId IdType="pubmed">28225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. . Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis b and c virus infections. J Virol (2009) 83(8):3719&#x2013;33. doi: 10.1128/JVI.01844-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01844-08</ArticleId><ArticleId IdType="pmc">PMC2663284</ArticleId><ArticleId IdType="pubmed">19176632</ArticleId></ArticleIdList></Reference><Reference><Citation>McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol (2010) 10(1):11&#x2013;23. doi: 10.1038/nri2674</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2674</ArticleId><ArticleId IdType="pmc">PMC3119211</ArticleId><ArticleId IdType="pubmed">20010788</ArticleId></ArticleIdList></Reference><Reference><Citation>French M, King M, Tschampa J. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication. J Infect Dis (2009) 200(8):1212&#x2013;5. doi: 10.1086/605890</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/605890</ArticleId><ArticleId IdType="pubmed">19728788</ArticleId></ArticleIdList></Reference><Reference><Citation>Guihot A, Dentone C, Assoumou L, Parizot C, Calin R. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS (2016) 30(2):327&#x2013;30. doi: 10.1097/QAD.0000000000000815</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000000815</ArticleId><ArticleId IdType="pubmed">26186129</ArticleId></ArticleIdList></Reference><Reference><Citation>Teigler JE, Leyre L, Chomont N, Slike B, Jian N, Eller MA, et al. . Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. Am Soc Clin Investig (2018) 3(10):1&#x2013;12. doi: 10.1172/jci.insight.98420</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.98420</ArticleId><ArticleId IdType="pmc">PMC6018979</ArticleId><ArticleId IdType="pubmed">29769442</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, Narv&#xe1; Ez AB, et al. . Immune activation set point during early HIV infection predicts subsequent CD4 T-cell changes independent of viral load. Blood (2004) 104:942&#x2013;7. doi: 10.1182/blood-2003-09-3333</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-09-3333</ArticleId><ArticleId IdType="pubmed">15117761</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L, Passmore JAS, Williamson C, Little F, Bebell LM, Mlisana K, et al. . Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 24(6):819&#x2013;31. doi: 10.1097/QAD.0b013e3283367836</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e3283367836</ArticleId><ArticleId IdType="pmc">PMC3001189</ArticleId><ArticleId IdType="pubmed">20224308</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonio R, Silvia M. Immunosuppression drug-related and clinical manifestation of coronavirus disease 2019: a therapeutical hypothesis. Am J Transplant (2020) 20(7):1947&#x2013;8. doi:&#xa0;10.1111/ajt.15905</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15905</ArticleId><ArticleId IdType="pmc">PMC7228280</ArticleId><ArticleId IdType="pubmed">32243698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, et al. . Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer (2020) 132:11&#x2013;6. doi: 10.1016/j.ejca.2020.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2020.03.021</ArticleId><ArticleId IdType="pmc">PMC7141482</ArticleId><ArticleId IdType="pubmed">32305831</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Jiang M, Xia D, He L, Lv X, Liao X, et al. . COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster. Clin Immunol (2020) 214:1&#x2013;4. doi: 10.1016/j.clim.2020.108413</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108413</ArticleId><ArticleId IdType="pmc">PMC7139268</ArticleId><ArticleId IdType="pubmed">32276139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussalino E, De Maria A, Russo R, Paoletti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report. Am J Transplant (2020) 20(7):1922&#x2013;4. doi: 10.1111/ajt.15920</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15920</ArticleId><ArticleId IdType="pmc">PMC7262360</ArticleId><ArticleId IdType="pubmed">32282991</ArticleId></ArticleIdList></Reference><Reference><Citation>Calza L, Bon I, Tadolini M, Borderi M, Colangeli V, Badia L, et al. . COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy. Infection (2020) 49(2):333&#x2013;7. doi:&#xa0;10.1007/s15010-020-01492-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-020-01492-7</ArticleId><ArticleId IdType="pmc">PMC7397968</ArticleId><ArticleId IdType="pubmed">32748333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: What decides the outcome? Nat Rev Immunol (2010) 10(7):514&#x2013;26. doi: 10.1038/nri2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2802</ArticleId><ArticleId IdType="pmc">PMC3899649</ArticleId><ArticleId IdType="pubmed">20577268</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. . Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother (2021) 27(2):387&#x2013;9. doi: 10.1016/j.jiac.2020.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7836222</ArticleId><ArticleId IdType="pubmed">33328135</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagrutta L, Sotelo CA, Estecho BR, Beorda WJ, Francos JL, Gonz&#xe1;lez Montaner P. La unidad febril de urgencias del hospital mu&#xf1;iz frente a COVID-19, HIV y tuberculosis. Med (2021) (Spanish: B Aires; ) 81(2):143&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33906130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozi&#x144;ska M, Augustynowicz-Kope&#x107; E. COVID-19 in patients with active tuberculosis. Diagnostics (2021) 11(10). doi: 10.3390/diagnostics11101768</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11101768</ArticleId><ArticleId IdType="pmc">PMC8534410</ArticleId><ArticleId IdType="pubmed">34679466</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan T, Xiao R, Lin G. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? FASEB J (2020) 34(5):6017&#x2013;26. doi: 10.1096/fj.202000782</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202000782</ArticleId><ArticleId IdType="pmc">PMC7264803</ArticleId><ArticleId IdType="pubmed">32306452</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. . Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Science (2020) 6:315&#x2013;31. doi: 10.1021/acscentsci.0c00272</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c00272</ArticleId><ArticleId IdType="pmc">PMC10467574</ArticleId><ArticleId IdType="pubmed">32226821</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev (2020) 53:13&#x2013;24. doi: 10.1016/j.cytogfr.2020.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7237916</ArticleId><ArticleId IdType="pubmed">32475759</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York city area. JAMA 323(20):2052&#x2013;9. doi: 10.1001/jama.2020.6775</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Masukume G, Mapanga W, Grinberg S, van Zyl DS. COVID-19 and HIV co-infection an emerging consensus. J Med Virol 93(1):170&#x2013;1. doi: 10.1002/jmv.26270</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26270</ArticleId><ArticleId IdType="pmc">PMC7361738</ArticleId><ArticleId IdType="pubmed">32633849</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou C, du Bruyn E, Stek C, Daroowala R, Goliath RT, Abrahams F, et al. . Relationship of SARS-CoV-2&#x2013;specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J Clin Invest (2021) 131(12):e149125. doi: 10.1172/JCI149125</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149125</ArticleId><ArticleId IdType="pmc">PMC8203446</ArticleId><ArticleId IdType="pubmed">33945513</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasim A, Mansour M, Kousa O, Awad D, Abuhazeem B, Millner P, et al. . A case of coronavirus disease 2019 in acquired immunodeficiency syndrome patient: A case report and review of the literature. Intractable Rare Dis Res (2020) 9(4):256&#x2013;9. doi: 10.5582/irdr.2020.03081</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/irdr.2020.03081</ArticleId><ArticleId IdType="pmc">PMC7586885</ArticleId><ArticleId IdType="pubmed">33139986</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondi A, Cimini E, Colavita F, Cicalini S, Pinnetti C, Matusali G, et al. . COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. J Med Virol (2021) 93(3):1796&#x2013;804. doi: 10.1002/jmv.26556</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26556</ArticleId><ArticleId IdType="pmc">PMC7537181</ArticleId><ArticleId IdType="pubmed">32975842</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. . Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in south Africa: a cohort study. (2021) 8(9):554&#x2013;67. doi: 10.1016/S2352-3018(21)00151-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00151-X</ArticleId><ArticleId IdType="pmc">PMC8336996</ArticleId><ArticleId IdType="pubmed">34363789</ArticleId></ArticleIdList></Reference><Reference><Citation>del Amo J, Polo R, Moreno S, D&#xed;az A, Mart&#xed;nez E, Arribas JR, et al. . Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral Therapy : A cohort study. Ann Intern Med (2020) 173(7):536&#x2013;41. doi:&#xa0;10.7326/M20-3689</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3689</ArticleId><ArticleId IdType="pmc">PMC7394316</ArticleId><ArticleId IdType="pubmed">32589451</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharov KS. HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes konstantin. Int J Infect Dis (2020) 102(2021):163&#x2013;9. doi:&#xa0;10.1016/j.ijid.2020.10.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.049</ArticleId><ArticleId IdType="pmc">PMC7585731</ArticleId><ArticleId IdType="pubmed">33115677</ArticleId></ArticleIdList></Reference><Reference><Citation>Calza L, Bon I, Borderi M, Colangeli V, Borioni A, Re MC, et al. . COVID-19 outcomes in uncontrolled HIV infection. (2021) 86(1):2020&#x2013;2. doi:&#xa0;10.1097/QAI.0000000000002537</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000002537</ArticleId><ArticleId IdType="pmc">PMC7727317</ArticleId><ArticleId IdType="pubmed">33065583</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 434(7037):1093&#x2013;7. doi: 10.1038/nature03501</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03501</ArticleId><ArticleId IdType="pubmed">15793563</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco JL, Ambrosioni J, Garcia F, Mart&#xed;nez E, Soriano A, Mallolas J, et al. . COVID-19 in patients with HIV: clinical case series. Lancet HIV (2020) 7:e314&#x2013;6. doi: 10.1016/S2352-3018(20)30111-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(20)30111-9</ArticleId><ArticleId IdType="pmc">PMC7159872</ArticleId><ArticleId IdType="pubmed">32304642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol (2020) 92(6):568&#x2013;76. doi: 10.1002/jmv.25748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25748</ArticleId><ArticleId IdType="pmc">PMC7228347</ArticleId><ArticleId IdType="pubmed">32134116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodionova IA, Schuster BM, Guinn KM, Sorci L, Scott DA, Li X, et al. . Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria. MBio (2014) 5(1):747&#x2013;60. doi: 10.1128/mBio.00747-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00747-13</ArticleId><ArticleId IdType="pmc">PMC3944813</ArticleId><ArticleId IdType="pubmed">24549842</ArticleId></ArticleIdList></Reference><Reference><Citation>Depaix A, Kowalska J. NAD analogs in aid of chemical biology and medicinal chemistry. Molecules (2019) 24(22):4187. doi: 10.3390/molecules24224187</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24224187</ArticleId><ArticleId IdType="pmc">PMC6891637</ArticleId><ArticleId IdType="pubmed">31752261</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab (2021) 33(3):479&#x2013;98. doi: 10.1016/j.cmet.2021.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.01.016</ArticleId><ArticleId IdType="pmc">PMC7825982</ArticleId><ArticleId IdType="pubmed">33529600</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R, Wentzel AR, Richards GA. COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Med Hypotheses (2020) 144:110044. doi: 10.1016/j.mehy.2020.110044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110044</ArticleId><ArticleId IdType="pmc">PMC7322475</ArticleId><ArticleId IdType="pubmed">32758884</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliori GB, Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Denholm J, et al. . Tuberculosis and COVID-19 co-infection: description of the global cohort. Eur Respir J (2022) 59(3):1&#x2013;15. doi:&#xa0;10.1183/13993003.02538-2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02538-2021).</ArticleId><ArticleId IdType="pmc">PMC8588566</ArticleId><ArticleId IdType="pubmed">34764184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Bolivar D, Intimayta-Escalante C, Cardenas-Jara A, Jandarov R, Huaman MA. COVID-19 case fatality rate and tuberculosis in a metropolitan setting. J Med Virol (2021) 93(5):3273&#x2013;6. doi: 10.1002/jmv.26868</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26868</ArticleId><ArticleId IdType="pmc">PMC8013772</ArticleId><ArticleId IdType="pubmed">33570198</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser S, Ellsworth M, Perez N, Hamilton H, Fletcher S, Brown D, et al. . Cerebral infarctions in an infant with COVID-19 delta variant infection and disseminated tuberculosis to. Pediatr Neurol (2022) 126:112&#x2013;3. doi: 10.1016/j.pediatrneurol.2021.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2021.10.014</ArticleId><ArticleId IdType="pmc">PMC8542513</ArticleId><ArticleId IdType="pubmed">34839267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheerin D, Abhimanyu, Peton N, Vo W, Allison CC, Wang X, et al. . Immunopathogenic overlap between COVID-19 and tuberculosis identified from transcriptomic meta-analysis and human macrophage infection. iScience (2022) 25(6):104464. doi: 10.1016/j.isci.2022.104464</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104464</ArticleId><ArticleId IdType="pmc">PMC9130411</ArticleId><ArticleId IdType="pubmed">35634577</ArticleId></ArticleIdList></Reference><Reference><Citation>Parolina L, Pshenichnaya N, Vasilyeva I, Lizinfed I, Urushadze N, Guseva V, et al. . Clinical characteristics of COVID-19 in TB patients and factors associated with the disease severity. Int J Infect Dis (2022) 124(Suppl 1):S82&#x2013;9. doi: 10.1016/j.ijid.2022.04.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.04.041</ArticleId><ArticleId IdType="pmc">PMC9040490</ArticleId><ArticleId IdType="pubmed">35483555</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;l &#x15e;, Akal&#x131;n Karaca ES, &#xd6;zg&#xfc;n Niksarl&#x131;o&#x11f;lu EY, &#xc7;&#x131;narka H, Uysal MA. Coexistence of tuberculosis and COVID-19 pneumonia: A presentation of 16 patients from Turkey with their clinical features. Tuberk Toraks. (2022) 70(1):8&#x2013;14. doi: 10.5578/tt.20229902</Citation><ArticleIdList><ArticleId IdType="doi">10.5578/tt.20229902</ArticleId><ArticleId IdType="pubmed">35362300</ArticleId></ArticleIdList></Reference><Reference><Citation>He G, Wu J, Shi J, Dai J, Gamber M, Jiang X, et al. . COVID-19 in tuberculosis patients: a report of three cases. J Med Virol (2020) 92(10):1802&#x2013;6. doi: 10.1002/jmv.25943</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25943</ArticleId><ArticleId IdType="pmc">PMC7267258</ArticleId><ArticleId IdType="pubmed">32343410</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi P, Khanna R, Reddy N, Patankar A, Patel S, Nair G, et al. . COVID-19 and tuberculosis co-infection in pregnancy - a case series and review. J Mother Child. (2021) 25(2):127&#x2013;34. doi:&#xa0;10.34763/jmotherandchild.20212502.d-21-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.34763/jmotherandchild.20212502.d-21-00002</ArticleId><ArticleId IdType="pmc">PMC8976590</ArticleId><ArticleId IdType="pubmed">34717056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaini J, Fadhillah MR, Reisa T, Isbaniah F, Handayani RRD. Tuberculosis and COVID-19 coinfection: A report of two cases at a tertiary referral in Indonesia. J Infect Dev Ctries. (2022) 16(3):478&#x2013;83. doi: 10.3855/jidc.15481</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.15481</ArticleId><ArticleId IdType="pubmed">35404853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gortaire EV, S&#xed;vori M, Jajati M, Trull&#xe1;s MF. ART&#xcd;CULO ORIGINAL COINFECCI&#xd3;N DE COVID-19 y TUBERCULOSIS EXTRAPULMONAR. Materiales y m&#xe9;todos (2022) 82(2):167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">35417378</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone L, Petruccioli E, Vanini V, Cuzzi G, Gualano G, Vittozzi P, et al. . Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. Int J Infect Dis (2021) 1135:582&#x2013;7. doi: 10.1016/j.ijid.2021.02.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.090</ArticleId><ArticleId IdType="pmc">PMC7944764</ArticleId><ArticleId IdType="pubmed">33713816</ArticleId></ArticleIdList></Reference><Reference><Citation>Amimo F, Lambert B, Magit A. What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? Trop Med Health (2020) 48(1):32. doi: 10.1186/s41182-020-00219-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41182-020-00219-6</ArticleId><ArticleId IdType="pmc">PMC7218555</ArticleId><ArticleId IdType="pubmed">32425653</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JE, Cohall D. Pharmacodynamics-a pharmacognosy perspective. pharmacognosy: Fundamentals, applications and strategy. (2017), 513&#x2013;25. doi: 10.1016/B978-0-12-802104-0.00026-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802104-0.00026-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamuzi JL, Birhanu AT, Shumba CS, Adetokunboh O, Uwimana-nico J, Haile ZT, et al. . Implications of COVID-19 in high burden HIV/TB countries : A systematic review of evidence. BMC Infect Dis (2020) 20(1):744. doi:&#xa0;10.1186/s12879-020-05450-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05450-4</ArticleId><ArticleId IdType="pmc">PMC7545798</ArticleId><ArticleId IdType="pubmed">33036570</ArticleId></ArticleIdList></Reference><Reference><Citation>
The global fund. global fund survey: Majority of HIV, TB and malaria programs face disruptions as a result of COVID-19 - COVID-19 - the global fund to fight AIDS, tuberculosis and malaria (2022). Available at: https://www.theglobalfund.org/en/covid-19/news/2020-06-17-global-fund-survey-majority-of-hiv-tb-and-malaria-programs-face-disruptions-as-a-result-of-covid-19/.</Citation></Reference><Reference><Citation>Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother (2020) 75(7):2013&#x2013;4. doi: 10.1093/jac/dkaa171</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa171</ArticleId><ArticleId IdType="pmc">PMC7239147</ArticleId><ArticleId IdType="pubmed">32417899</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother (2020) 64(5). doi: 10.1128/AAC.00399-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00399-20</ArticleId><ArticleId IdType="pmc">PMC7179632</ArticleId><ArticleId IdType="pubmed">32152082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitj&#xe0; O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Heal (2020) 8(5):e639&#x2013;40. doi: 10.1016/S2214-109X(20)30114-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30114-5</ArticleId><ArticleId IdType="pmc">PMC7104000</ArticleId><ArticleId IdType="pubmed">32199468</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. . The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A. (2018) 115(45):11613&#x2013;8. doi: 10.1073/pnas.1811345115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1811345115</ArticleId><ArticleId IdType="pmc">PMC6233120</ArticleId><ArticleId IdType="pubmed">30352857</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennings PS. HIV Drug resistance : problems and perspectives. Infect Dis Rep (2013) 5(1):21&#x2013;5. doi:&#xa0;10.4081/idr.2013.s1.e5</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/idr.2013.s1.e5</ArticleId><ArticleId IdType="pmc">PMC3892620</ArticleId><ArticleId IdType="pubmed">24470969</ArticleId></ArticleIdList></Reference><Reference><Citation>Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob (2020) 19(1):1&#x2013;6. doi: 10.1186/s12941-020-00363-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-020-00363-1</ArticleId><ArticleId IdType="pmc">PMC7245173</ArticleId><ArticleId IdType="pubmed">32446305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters F, Van De Bovenkamp J, Van Den Bosch B, Van Den Brink S, Broeders M, Hoa N, et al. . Multi-center evaluation of cepheid xpert&#xae; xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic. J Clin Virol J (2020) 128(2020):104426. doi:&#xa0;10.1016/j.jcv.2020.104426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104426</ArticleId><ArticleId IdType="pmc">PMC7211760</ArticleId><ArticleId IdType="pubmed">32417674</ArticleId></ArticleIdList></Reference><Reference><Citation>Erving G. Stigma : notes on the management of spoiled identity Vol. p. Englewood Cliffs NJ, editor. (Touchstone Publisher, New York United States of America: Prentice-Hall; ) (1963) p. 1&#x2013;147.</Citation></Reference><Reference><Citation>Tornheim JA, Dooley KE. Tuberculosis associated with HIV infection. Microbiol Spectr. (2017) 5(1):1&#x2013;16. doi: 10.1128/9781555819866.ch34</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/9781555819866.ch34</ArticleId><ArticleId IdType="pubmed">28233512</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . . social stigma associated with COVID-19 (2020). Available at: https://www.who.int/publications/i/item/social-stigma-associated-with-covid-19.</Citation></Reference><Reference><Citation>Dolatian M, Ghiasi N, Valizadeh R, Kellner SJ, Mahmoodi Z, Nanbakhsh M. SARS, MERS and COVID-19 status in HIV-positive patients: A systematic review. J Cell Mol Anesth (2021) 6(1):75&#x2013;80. doi:&#xa0;10.22037/jcma.v6i1.32203</Citation><ArticleIdList><ArticleId IdType="doi">10.22037/jcma.v6i1.32203</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CY, Wong KY, Law TSG, Shum TT, Li YK, Pang WK. Tuberculosis in a SARS outbreak. J Chin Med Assoc (2004) 67(11):579&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15720073</ArticleId></ArticleIdList></Reference><Reference><Citation>
Liu W, Fontanet A, Zhang P-H, Zhan L, Xin Z-T, Tang F, et al. . Pulmonary tuberculosis and SARS, China (2006). Available at: https://stacks.cdc.gov/view/cdc/15869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3294680</ArticleId><ArticleId IdType="pubmed">16715587</ArticleId></ArticleIdList></Reference><Reference><Citation>Low JG, Lee CC, Leo YS, Low JGH, Lee CC, Leo YS. Severe acute respiratory syndrome and pulmonary tuberculosis. Clin Infect Dis (2004) 38(12):e123-5. doi: 10.1086/421396</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/421396</ArticleId><ArticleId IdType="pmc">PMC7107818</ArticleId><ArticleId IdType="pubmed">15227635</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. Middle East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: Implications for infection control. Intervirology (2017) 60(1&#x2013;2):53&#x2013;5. doi: 10.1159/000477908</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000477908</ArticleId><ArticleId IdType="pmc">PMC7179530</ArticleId><ArticleId IdType="pubmed">28683463</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlman DC, El-Helou P, Salomon N. Tuberculosis in patients with human immunodeficiency virus infection. Semin Respir Infect (1999) 14(4):344&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10638514</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente P, Suleman A. COVID-19 in Europe: from outbreak to vaccination. BMC Public Heal (2022) 22(1):1&#x2013;17. doi:&#xa0;10.1186/s12889-022-14454-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14454-5</ArticleId><ArticleId IdType="pmc">PMC9716177</ArticleId><ArticleId IdType="pubmed">36461031</ArticleId></ArticleIdList></Reference><Reference><Citation>
Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis (2022) 22(9):1293&#x2013;302. http://www.thelancet.com/article/S1473309922003206/fulltext. doi: 10.1016/S1473-3099(22)00320-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>